Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03118583 · ClinicalTrials.gov registry record · NA
Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers
A NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT03118583: Completed NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
NCT03118583 is a NA study that has completed, run by Midwest Center for Metabolic and Cardiovascular Research. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03118583, a NA study, has completed, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this study is to assess the effects of a dietary supplement on fasting lipoprotein lipids and a marker of inflammation in men and women with levels of low-density lipoprotein cholesterol above desirable levels.
Primary Outcome
Percent change in LDL-C from baseline (average of values at days -7 and 0) to end of treatment (average of values at days 21 and 28)
Interventions
- DIETARY_SUPPLEMENT 300 mg/day of dietary supplement containing carrageenan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2018-01-31 |
| Phase | NA |
What the finished NCT03118583 record still lists
NCT03118583 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which 300 mg/day of dietary supplement containing carrageenan is the first listed.
NCT03118583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03118583 about?
NCT03118583 is a clinical study titled "Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers". The goal of this study is to assess the effects of a dietary supplement on fasting lipoprotein lipids and a marker of inflammation in men and women with levels of low-density lipoprotein cholesterol above desirable levels.
What is the current status of trial NCT03118583?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2017-03-15. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT03118583?
The interventions under investigation include: 300 mg/day of dietary supplement containing carrageenan (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03118583?
This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03118583's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI